收藏切换
Efficacy of sintilimab combined with sorafenib in the treatment of advanced liver cancer
收藏切换
Qingwei LI, Wei LI, Jidong YANG, Peng WU*
World Clinical Drug | 2024, 45(1) : 66 - 70
Less
收藏切换
World Clinical Drug | 2024, 45(1): 66-70
• Article •
Efficacy of sintilimab combined with sorafenib in the treatment of advanced liver cancer
Full
Qingwei LI, Wei LI, Jidong YANG, Peng WU*
Affiliations
  • Department of Vascular Intervention, Jingmen Second People's Hospital, Jingmen 448000, Hubei Province, China
Published: 2024-01-10 doi: 10.13683/j.wph.2024.01.011
Outline
收藏切换
Objective

To investigate the efficacy of sintilimab combined with sorafenib in the treatment of advanced liver cancer and its influence on serum alpha fetoprotein (AFP) and protein induced by vitamin K absence or antagonist Ⅱ (PIVKA-Ⅱ).

Methods

A total of 88 patients with advanced liver cancer treated in our hospital from April 2019 to June 2020 were selected and divided into control group and combined group according to random number table method. The control group given conventional treatment combined with sorafenib, and the combined group was given sintilimab on the basis of the control group, with 44 cases in each group. The disease control rates, liver function index, AFP and PIVKA-Ⅱlevels were compared between the two groups. The adverse reactions of patients and the median survival situation were observed.

Results

After treatment, the disease control rate of the combined group was higher than that of the control group (90.91% vs 72.73%, χ2=4.889, P=0.027). The levels of alanine aminotransferase, total bilirubin, AFP and PIVKA-Ⅱin both groups were lower than before treatment, and albumin was higher than before treatment, and the combined group was better than the control group, and the difference was statistically significant (P<0.05). The median survival time of the combined group was longer than that of the control group, and the difference was statistically significant (t=8.095, P<0.001). The 2-year survival rate in the combined group (17/44, 38.64%) was higher than that in the control group (8/44, 18.18%, χ2=5.320, P=0.021).

Conclusion

Sintilimab combined with sorafenib has good efficacy in the treatment of advanced liver cancer, can effectively improve the liver function of patients, and has a certain safety, worthy of clinical promotion and application.

sintilimab  /  sorafenib  /  advanced liver cancer  /  alpha fetoprotein  /  protein induced by vitamin K absence or antagonist Ⅱ
李庆伟, 李威, 杨继东, 吴鹏. 信迪利单抗联合索拉非尼对晚期肝癌的疗效分析. 世界临床药物, 2024 , 45 (1) : 66 -70 . DOI: 10.13683/j.wph.2024.01.011
Qingwei LI, Wei LI, Jidong YANG, Peng WU. Efficacy of sintilimab combined with sorafenib in the treatment of advanced liver cancer[J]. World Clinical Drug, 2024 , 45 (1) : 66 -70 . DOI: 10.13683/j.wph.2024.01.011
Year 2024 volume 45 Issue 1
12
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.01.011
  • Receive Date:2022-11-21
  • Online Date:2026-11-18
  • Published:2024-01-10
Article Data
Affiliations
History
  • Received:2022-11-21
  • Revised:2023-06-29
Affiliations
    Department of Vascular Intervention, Jingmen Second People's Hospital, Jingmen 448000, Hubei Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.01.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT